Cancers, Vol. 11, Pages 1489: Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma

Cancers, Vol. 11, Pages 1489: Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma Cancers doi: 10.3390/cancers11101489 Authors: Bol Ellebaek Hoejberg Bagger Larsen Klausen Køhler Schmidt Bastholt Kiilgaard Donia Svane Uveal melanoma (UM) is the most common intraocular malignancy in adults and shows a high rate of metastatic spread. As randomized clinical trials with immune checkpoint inhibitors (ICI) have not been performed in patients with metastatic UM, we analyzed the real-world outcomes in a nationwide population-based study. Clinical data of patients with UM were extracted from the Danish Metastatic Melanoma database, a nationwide database containing unselected records of patients diagnosed with metastatic melanoma in Denmark. Survival before (pre-ICI, n = 32) and after (post-ICI, n = 94) the approval of first-line treatment with ICI was analyzed. A partial response to first-line treatment was observed in 7% of patients treated with anti-programmed cell death protein (PD)-1 monotherapy and in 21% with combined anti-cytotoxic T lymphocyte antigen (CTLA)-4 plus anti-PD-1 therapy. Median progression-free survival was 2.5 months for patients treated in the pre-ICI era compared to 3.5 months in the post-ICI era (hazard ratio (HR) 0.43; 95% confidence interval (CI) 0.28–0.67; p < 0.001). The estimated one-year overall survival rate increased from 25.0% to 41.9% and the median overall...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research